This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kouvaris, J. R. Articles by Vlahos, L. J. Search for Related Content PubMed PubMed Citation Articles by Kouvaris, J. R. Articles by Vlahos, L. J.

Symptom Management and Supportive Care

Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector

^aAretaieion Hospital University of Athens, Athens, Greece; ^bAttikon Hospital University of Athens, Athens, Greece

Key Words. Amifostine • Radiotherapy • Radiation toxicities • Mucositis • Xerostomia

Correspondence: John R. Kouvaris, M.D., Aretaieion Hospital, Department of Radiology, 76 Vas Sophias Avenue, Athens 11528, Greece. Telephone: 00302107286319; Fax: 00302107220253; e-mail: johnkouv{at}aretaieio.uoa.gr

After several decades of preclinical and clinical research, the first approved radioprotective drug, amifostine, is being used in clinical practice.

Amifostine has been shown to specifically protect normal tissues from damage caused by radiation and chemotherapy. An inactive prodrug, amifostine is converted to an active thiol by dephosphorylation by alkaline phosphatase in the normal endothelium. The hypovascularity and acidity of the tumor environment and the differential expression of alkaline phosphatase in normal and neoplastic tissues contribute to its cytoprotective selectivity. The cytoprotective mechanism of amifostine is complicated, involving free-radical scavenging, DNA protection and repair acceleration, and induction of cellular hypoxia. The U.S. Food and Drug Administration has approved the i.v. use of amifostine to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer and to reduce the incidence of moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands. Nonetheless, amifostine has potential applications in many other oncologic settings. Novel schedules and routes of administration are under investigation and may further simplify the use of amifostine, reduce any undesired effects, and considerably broaden its applications. This review summarizes the clinical experience with amifostine and provides insight into future clinical directions.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				M. Machtay, J. Moughan, A. Trotti, A. S. Garden, R. S. Weber, J. S. Cooper, A. Forastiere, and K. K. Ang Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis J. Clin. Oncol., July 20, 2008; 26(21): 3582 - 3589. [Abstract] [Full Text] [PDF]